search
Back to results

BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

Primary Purpose

Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung

Status
Active
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
Nivolumab, Ipilimumab
Nivolumab, Ipilimumab
Sponsored by
Lung Cancer Group Cologne
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Carcinoma, Non-Small-Cell Lung focused on measuring Nivolumab, Ipilimumab

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Note: Cohort 1 is closed for enrollment

Inclusion Criteria:

  • Cohort 1: Subjects with histologically or cytologically confirmed advanced non-squamous non-small cell lung cancer who present with stage IIIB or stage IV disease after failure of platinum-based first-line therapy. Subjects who received adjuvant/neoadjuvant therapy or definitive chemoradiation and develop recurrence or progression, with evidence of stage IIIB-IV disease within 6 months after completion of therapy, are eligible.
  • Cohort 2: Subjects in Cohort 2 have to undergo Prescreening to determine Tumor Mutation Burden. Only patients with high Tumor Mutation Burden are eligible.

Subjects with histologically or cytologically confirmed limited-stage or extensive-stage small cell lung cancer after failure of platinum-based first-line therapy.

Cohort 1 and Cohort 2:

  • Signed and dated written informed consent form must be obtained before the performance of any study-specific procedure
  • Male or female patients ≥ 18 years of age
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
  • Subjects must be willing to undergo at least 2 biopsies (baseline and before start of Treatment Part B)
  • Subjects must be considered as suitable for the conduction of 2 biopsies (baseline and in case of progression) by the responsible local investigator
  • Measurable disease by CT or MRI per RECIST 1.1 criteria.
  • Screening laboratory values must meet the following criteria and should be obtained within 28 days prior to registration: white blood cell count ≥ 2000/μL, Neutrophils ≥ 1500/μL, Platelets ≥ 100 x103/μL, Hemoglobin > 9.0 g/dL, Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or creatinine clearance (CrCl) ≥ 40 mL/min, AST/ALT ≤ 3 x ULN for patients without liver metastasis, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 5 x ULN for patients with liver metastasis, Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
  • Prior chemotherapy must have been completed at least 4 weeks before study drug administration, and all AEs have either returned to baseline or stabilized.
  • Prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration
  • Prior targeted therapy must have been completed at least 4 weeks prior to study drug administration
  • Subjects with central nervous system (CNS) metastasis are eligible if CNS metastases are treated and subjects have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 28 days prior to first dose of study drug administration. In addition, subjects must either be off corticosteroids or on a stable dose or decreasing dose of ≤ 10 mg daily prednisone (or equivalent).
  • Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception and must agree to use adequate method to avoid pregnancy for 5 month after the last dose of study drug.
  • Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of b-HCG) within 24 hours prior to the start of nivolumab.
  • Women must not be breastfeeding.
  • Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP must be willing to adhere to contraception for a period of 7 month post treatment completion.

Exclusion Criteria:

  • Subjects with squamous cell NSCLC
  • Cohort 1: activating epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation
  • Medical conditions associated with significantly increased risk for bleeding complications caused by biopsy procedures (e.g. known coagulopathies, therapeutic anticoagulation)
  • Active brain metastases or leptomeningeal metastases. Subjects with brain metastases are eligible if metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for 4 weeks after treatment is complete and within 28 days prior to the first dose of study drug administration. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration.
  • Presence or history of any other primary malignancy other than NSCLC for Cohort 1 and SCLC for Cohort 2 within 5 years prior to enrolment into the trial, except for adequately treated basal or squamous cell carcinoma of the skin or any adequately treated in situ carcinoma.
  • Active, known or suspected autoimmune disease. Subjects are permitted to enrol if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.
  • Positive test for hepatitis B or hepatitis C indicating acute or chronic infection
  • Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
  • Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first dose of study drug administration. Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
  • Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
  • Prior systemic treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.
  • Prisoners or subjects who are involuntarily incarcerated
  • Any other serious or uncontrolled medical disorder, active infections, physical exam findings, laboratory finding, altered mental status, or psychiatric condition that, in the opinion of the investigator, would limit a subject's ability to comply with the study requirements, substantially increase risk to the subject, or impact the interpretability or study results.
  • Allergies and Adverse Drug Reaction: History of allergy to study drug components and history of severe hypersensitivity reaction to any monoclonal antibody
  • Current treatment within another therapeutic clinical trial

Sites / Locations

  • SLK-Fachklinik Löwenstein
  • Universitätsklinikum Tübingen, Innere Medizin VIII - Medizinische Onkologie und Pneumologie
  • Universitätsklinikum Würzburg - Comprehensive Cancer Center Mainfranken
  • Universitätsklinikum Frankfurt - Medizinische Klinik II
  • Klinikum Kassel - Klinik für Hämatologie und Onkologie
  • Pius Hospital Oldenburg
  • Uniklinik RWTH - Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzellentransplantation
  • Universitätsklinikum Bonn - Medizinische Klinik und Poliklinik III
  • University Hospital Cologne
  • Kliniken der Stadt Köln - Lungenkrebszentrum Köln-Merheim
  • St.-Johannes-Hospital Dortmund
  • Uniklinik Düsseldorf - Klinik für Hämatologie und Onkologie
  • Lungenklinik Hemer
  • Universitätsklinikum Münster - Medizinische Klinik A, Pneumologie
  • Malteser Krankenhaus St. Franziskus-Hospital
  • Evangelische Lungenklinik Berlin

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Cohort 1, NSCLC

Cohort 2, SCLC

Arm Description

During Treatment Part A nivolumab 240 mg IV q2w as monotherapy is administered. At the time of disease progression a re-biopsy is performed before initiation of combination therapy (Treatment Part B). Within Treatment Part B, nivolumab is given in a dose of 3 mg/kg q2w together with ipilimumab 1 mg/kg IV q6w.

Within Treatment Part A, nivolumab 1 mg/kg q3w together with ipilimumab 3 mg/kg q3w for a total of four doses is administered. After the four combined doses have been administered, a re-biopsy is performed before initiation of Treatment Part B. In Treatment Part B, nivolumab 240 mg q2w monotherapy is administered until disease progression or unacceptable toxicity

Outcomes

Primary Outcome Measures

Cohort 1: ORR after addition of ipilimumab to nivolumab treatment.
ORR is defined as proportion of patients with reduction in tumor burden as assessed by RECIST 1.1 criteria (investigator-assessed).
Cohort 2: ORR of the combination therapy nivolumab and ipilimumab.
ORR is defined as proportion of patients with reduction in tumor burden as assessed by RECIST 1.1 criteria (investigator-assessed).

Secondary Outcome Measures

Overall survival of nivolumab monotherapy/nivolumab + ipilimumab combination therapy
Time from date of first dose to the date of death to any cause.
Progression-free survival of nivolumab monotherapy/nivolumab + ipilimumab combination therapy
Time from the date of first dose to first documentation of objective disease progression or to death on study due to any cause, whichever occurs first.
Duration of response of nivolumab monotherapy/nivolumab + ipilimumab combination therapy
Time from the first documentation of objective tumor response (CR or PR) that is subsequently confirmed to the first documentation of objective disease progression or to death due to any cause, whichever occurs first
Incidence, severity and grading of adverse events (AEs) during nivolumab monotherapy/ nivolumab + ipilimumab combination therapy
Adverse events are documented according to the Common Terminology Criteria for Adverse Events (CTCAE)
Incidence, severity and grading of serious adverse events (SAEs) during nivolumab monotherapy/ nivolumab + ipilimumab combination therapy
Serious adverse events are documented according to the Common Terminology Criteria for Adverse Events (CTCAE)

Full Information

First Posted
March 2, 2017
Last Updated
October 18, 2023
Sponsor
Lung Cancer Group Cologne
Collaborators
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT03083691
Brief Title
BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer
Official Title
A Phase II Trial of Nivolumab in Combination With Ipilimumab to Evaluate Efficacy and Safety Relapsed in Lung Cancer and to Evaluate Biomarkers Predictive for Response to Immune Checkpoint Inhibition
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 13, 2017 (Actual)
Primary Completion Date
August 31, 2022 (Actual)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lung Cancer Group Cologne
Collaborators
Bristol-Myers Squibb

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
BIOLUMA is a multicentric non-randomised phase II trial in patients with non-squamous non-small cell lung cancer (NSCLC) (Cohort 1) and patients with small-cell lung cancer (SCLC) (Cohort 2) after failure of platinum-based first-line therapy. NSCLC patients are treated with nivolumab until disease progression and subsequently receive a combination therapy of nivolumab and ipilimumab. SCLC patients receive four cycles of nivolumab in combination with ipilimumab and subsequent nivolumab monotherapy. Primary endpoint for both cohorts is overall response rate of combination therapy. Within the diagnostic part tumor biopsies will be analysed. Tumor tissue will be obtained before initiation of therapy and after progression on nivolumab monotherapy before addition of ipilimumab in Cohort 1 and after completion of the four nivolumab/ipilimumab combination cycles before continuation of nivolumab monotherapy in Cohort 2, respectively. Flow cytometry of blood samples and microbiome analysis of deep rectal swaps are performed prior to therapy as well as during course of treatment. Cohort 1 (NSCLC) is closed for enrollment due to Sponsor decision. In Cohort 2 (SCLC) a prescreening for high Tumor Mutation Burden is necessary before enrollment.
Detailed Description
Cohort 2 (SCLC) has been subdivided by amendment in Cohort 2a without prescreening and Cohort 2b with TMB-prescreening. For Cohort 2a enrollment has been stopped in December 2017. Cohort 2b is closed for enrollment as the cohort is fully recruited.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung
Keywords
Nivolumab, Ipilimumab

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
The treatment period is subdivided in Treatment Part A and B which differ between the two cohorts: Cohort 1 (non-squamous NSCLC): During Treatment Part A nivolumab 240 mg IV q2w as monotherapy is administered. At time of disease progression another re-biopsy is mandatory before initiation of combination therapy (Treatment Part B). Within Treatment Part B, nivolumab is given in a dose of 3 mg/kg q2w together with ipilimumab 1 mg/kg IV q6w. Cohort 2 (SCLC): Patients have to undergo a prescreening for high Tumor Mutation Burden. Within Treatment Part A, nivolumab 1 mg/kg q3w together with ipilimumab 3 mg/kg q3w for a total of four doses is administered. After the four combined doses have been administered, another re-biopsy is mandatory before initiation of Treatment Part B. In Treatment Part B, nivolumab 240 mg q2w monotherapy is administered until disease progression or unacceptable toxicity.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
90 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1, NSCLC
Arm Type
Other
Arm Description
During Treatment Part A nivolumab 240 mg IV q2w as monotherapy is administered. At the time of disease progression a re-biopsy is performed before initiation of combination therapy (Treatment Part B). Within Treatment Part B, nivolumab is given in a dose of 3 mg/kg q2w together with ipilimumab 1 mg/kg IV q6w.
Arm Title
Cohort 2, SCLC
Arm Type
Other
Arm Description
Within Treatment Part A, nivolumab 1 mg/kg q3w together with ipilimumab 3 mg/kg q3w for a total of four doses is administered. After the four combined doses have been administered, a re-biopsy is performed before initiation of Treatment Part B. In Treatment Part B, nivolumab 240 mg q2w monotherapy is administered until disease progression or unacceptable toxicity
Intervention Type
Drug
Intervention Name(s)
Nivolumab, Ipilimumab
Intervention Description
Cohort 1: addition of ipilimumab in case of progression on nivolumab monotherapy.
Intervention Type
Drug
Intervention Name(s)
Nivolumab, Ipilimumab
Intervention Description
Cohort 2: upfront combination therapy of nivolumab and ipilimumab for four cycles, followed by nivolumab monotherapy.
Primary Outcome Measure Information:
Title
Cohort 1: ORR after addition of ipilimumab to nivolumab treatment.
Description
ORR is defined as proportion of patients with reduction in tumor burden as assessed by RECIST 1.1 criteria (investigator-assessed).
Time Frame
From beginning of combination therapy until the date of first documented progression, or date of death of any cause, whichever occurs first, assessed up to 120 months.
Title
Cohort 2: ORR of the combination therapy nivolumab and ipilimumab.
Description
ORR is defined as proportion of patients with reduction in tumor burden as assessed by RECIST 1.1 criteria (investigator-assessed).
Time Frame
From beginning of combination therapy until the date of first documented progression, or date of death of any cause, whichever occurs first, assessed up to 120 months.
Secondary Outcome Measure Information:
Title
Overall survival of nivolumab monotherapy/nivolumab + ipilimumab combination therapy
Description
Time from date of first dose to the date of death to any cause.
Time Frame
From date of first dose until death, withdrawal of informed consent or lost to follow-up, through study completion, an average of 1 year, up to 120 months.
Title
Progression-free survival of nivolumab monotherapy/nivolumab + ipilimumab combination therapy
Description
Time from the date of first dose to first documentation of objective disease progression or to death on study due to any cause, whichever occurs first.
Time Frame
From date of first dose to first documentation of objective disease progression or to death on study due to any cause, an average of 6 months, up to 120 months.
Title
Duration of response of nivolumab monotherapy/nivolumab + ipilimumab combination therapy
Description
Time from the first documentation of objective tumor response (CR or PR) that is subsequently confirmed to the first documentation of objective disease progression or to death due to any cause, whichever occurs first
Time Frame
First on-study tumor assessment is performed at Week 9 in Cohort 1 and at Week 5 in Cohort 2 and subsequently every 8 weeks through study completion, an average of 1 year.
Title
Incidence, severity and grading of adverse events (AEs) during nivolumab monotherapy/ nivolumab + ipilimumab combination therapy
Description
Adverse events are documented according to the Common Terminology Criteria for Adverse Events (CTCAE)
Time Frame
From initiation of study drug, continuously during the treatment period and for a minimum of 100 days following the last dose of study treatment.
Title
Incidence, severity and grading of serious adverse events (SAEs) during nivolumab monotherapy/ nivolumab + ipilimumab combination therapy
Description
Serious adverse events are documented according to the Common Terminology Criteria for Adverse Events (CTCAE)
Time Frame
Following the subject's written consent, SAEs are collected that occur within survival follow-up through study completion, an average of 6 months. For subjects who did not receive study medication, SAEs are collected until resolved.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Note: Both cohorts are closed for enrollment Inclusion Criteria: Cohort 1: Subjects with histologically or cytologically confirmed advanced non-squamous non-small cell lung cancer who present with stage IIIB or stage IV disease after failure of platinum-based first-line therapy. Subjects who received adjuvant/neoadjuvant therapy or definitive chemoradiation and develop recurrence or progression, with evidence of stage IIIB-IV disease within 6 months after completion of therapy, are eligible. Cohort 2: Subjects in Cohort 2 have to undergo Prescreening to determine Tumor Mutation Burden. Only patients with high Tumor Mutation Burden are eligible. Subjects with histologically or cytologically confirmed limited-stage or extensive-stage small cell lung cancer after failure of platinum-based first-line therapy. Cohort 1 and Cohort 2: Signed and dated written informed consent form must be obtained before the performance of any study-specific procedure Male or female patients ≥ 18 years of age Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 Subjects must be willing to undergo the baseline biopsie during screening, if medically feasible Measurable disease by CT or MRI per RECIST 1.1 criteria. Screening laboratory values must meet the following criteria and should be obtained within 28 days prior to registration: white blood cell count ≥ 2000/μL, Neutrophils ≥ 1500/μL, Platelets ≥ 100 x103/μL, Hemoglobin > 9.0 g/dL, Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or creatinine clearance (CrCl) ≥ 40 mL/min, AST/ALT ≤ 3 x ULN for patients without liver metastasis, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 5 x ULN for patients with liver metastasis, Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) Prior chemotherapy must have been completed at least 4 weeks before study drug administration, and all AEs have either returned to baseline or stabilized. Prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration Prior targeted therapy must have been completed at least 4 weeks prior to study drug administration Cohort 1 and 2a: Subjects with central nervous system (CNS) metastasis are eligible if CNS metastases are treated and subjects have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 28 days prior to first dose of study drug administration. In addition, subjects must either be off corticosteroids or on a stable dose or decreasing dose of ≤ 10 mg daily prednisone (or equivalent). Cohort 2b: Subjects with CNS metastases are eligible. Radiation of CNS metastases at initiation of study drug treatment is allowed if the trial subject has target lesions outside of the brain. Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception and must agree to use adequate method to avoid pregnancy for 5 month after the last dose of study drug. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of b-HCG) within 24 hours prior to the start of nivolumab. Women must not be breastfeeding. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP must be willing to adhere to contraception for a period of 7 month post treatment completion. Exclusion Criteria: Subjects with squamous cell NSCLC Cohort 1: activating epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation Cohort 1 and 2a only: More than one prior line of chemotherapy for treatment of advanced disease Note for Cohort 2b: inclusion of patients who received 2nd line treatment is allowed if 2nd line did not include an anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-CTLA-4 antibody as monotherapy or in combination with other than platinum-based chemotherapy. Medical conditions associated with significantly increased risk for bleeding complications caused by biopsy procedures (e.g. known coagulopathies, therapeutic anticoagulation) Cohort 1 and 2a only: Patients are excluded if they have active brain metastases or leptomeningeal metastases. Subjects with brain metastases are eligible if metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for 4 weeks after treatment is complete and within 28 days prior to the first dose of study drug administration. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration. Presence or history of any other primary malignancy other than NSCLC for Cohort 1 and SCLC for Cohort 2 within 5 years prior to enrolment into the trial, except for adequately treated basal or squamous cell carcinoma of the skin or any adequately treated in situ carcinoma. Active, known or suspected autoimmune disease. Subjects are permitted to enrol if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger. Positive test for hepatitis B or hepatitis C indicating acute or chronic infection Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first dose of study drug administration. Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease. Note for Cohort 2b: higher doses of corticosteroids for patients receiving radiation therapy of brain metastases are allowed. Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity Prior systemic treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways. Note: SCLC-Patients who where treated with a combination therapy of platinum-based chemotherapy together with anti-PD-1/PD-L1 treatment are eligible. Prisoners or subjects who are involuntarily incarcerated. Any other serious or uncontrolled medical disorder, active infections, physical exam findings, laboratory finding, altered mental status, or psychiatric condition that, in the opinion of the investigator, would limit a subject's ability to comply with the study requirements, substantially increase risk to the subject, or impact the interpretability or study results. Allergies and Adverse Drug Reaction: History of allergy to study drug components and history of severe hypersensitivity reaction to any monoclonal antibody Current treatment within another therapeutic clinical trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jürgen Wolf, MD
Organizational Affiliation
University ClinicCologne
Official's Role
Principal Investigator
Facility Information:
Facility Name
SLK-Fachklinik Löwenstein
City
Löwenstein
State/Province
Baden-Wuerttemberg
ZIP/Postal Code
74245
Country
Germany
Facility Name
Universitätsklinikum Tübingen, Innere Medizin VIII - Medizinische Onkologie und Pneumologie
City
Tübingen
State/Province
Baden-Wuerttemberg
ZIP/Postal Code
72076
Country
Germany
Facility Name
Universitätsklinikum Würzburg - Comprehensive Cancer Center Mainfranken
City
Würzburg
State/Province
Bavaria
ZIP/Postal Code
97080
Country
Germany
Facility Name
Universitätsklinikum Frankfurt - Medizinische Klinik II
City
Frankfurt am Main
State/Province
Hessen
ZIP/Postal Code
60590
Country
Germany
Facility Name
Klinikum Kassel - Klinik für Hämatologie und Onkologie
City
Kassel
State/Province
Hessen
ZIP/Postal Code
34125
Country
Germany
Facility Name
Pius Hospital Oldenburg
City
Oldenburg
State/Province
Lower Saxony
ZIP/Postal Code
26121
Country
Germany
Facility Name
Uniklinik RWTH - Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzellentransplantation
City
Aachen
State/Province
North Rhine-Westphalia
ZIP/Postal Code
52074
Country
Germany
Facility Name
Universitätsklinikum Bonn - Medizinische Klinik und Poliklinik III
City
Bonn
State/Province
North Rhine-Westphalia
ZIP/Postal Code
53127
Country
Germany
Facility Name
University Hospital Cologne
City
Cologne
State/Province
North Rhine-Westphalia
ZIP/Postal Code
50937
Country
Germany
Facility Name
Kliniken der Stadt Köln - Lungenkrebszentrum Köln-Merheim
City
Cologne
State/Province
North Rhine-Westphalia
ZIP/Postal Code
51109
Country
Germany
Facility Name
St.-Johannes-Hospital Dortmund
City
Dortmund
State/Province
North Rhine-Westphalia
ZIP/Postal Code
44137
Country
Germany
Facility Name
Uniklinik Düsseldorf - Klinik für Hämatologie und Onkologie
City
Düsseldorf
State/Province
North Rhine-Westphalia
ZIP/Postal Code
40225
Country
Germany
Facility Name
Lungenklinik Hemer
City
Hemer
State/Province
North Rhine-Westphalia
ZIP/Postal Code
58675
Country
Germany
Facility Name
Universitätsklinikum Münster - Medizinische Klinik A, Pneumologie
City
Münster
State/Province
North Rhine-Westphalia
ZIP/Postal Code
48149
Country
Germany
Facility Name
Malteser Krankenhaus St. Franziskus-Hospital
City
Flensburg
State/Province
Schleswig-Holstein
ZIP/Postal Code
24939
Country
Germany
Facility Name
Evangelische Lungenklinik Berlin
City
Berlin
ZIP/Postal Code
13125
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

We'll reach out to this number within 24 hrs